Karyopharm to Participate at the 2025 RBC Capital Markets Global Healthcare Conference
Karyopharm Therapeutics (Nasdaq: KPTI), a commercial-stage pharmaceutical company focused on novel cancer therapies, has announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference. The company's senior management team will engage in a fireside chat on Wednesday, May 21 at 10:00 a.m. ET in New York. Investors and interested parties can access a live webcast of the presentation through the company's investor relations website, with a replay available after the event.
Karyopharm Therapeutics (Nasdaq: KPTI), un'azienda farmaceutica in fase commerciale specializzata in terapie innovative contro il cancro, ha annunciato la sua partecipazione alla 2025 RBC Capital Markets Global Healthcare Conference. Il team di alta dirigenza dell'azienda parteciperà a una conversazione informale il mercoledì 21 maggio alle 10:00 ET a New York. Investitori e interessati potranno seguire la presentazione in diretta streaming tramite il sito web delle relazioni con gli investitori dell'azienda, con la possibilità di rivederla in differita dopo l'evento.
Karyopharm Therapeutics (Nasdaq: KPTI), una compañía farmacéutica en etapa comercial enfocada en terapias innovadoras contra el cáncer, ha anunciado su participación en la Conferencia Global de Salud 2025 de RBC Capital Markets. El equipo directivo senior de la empresa participará en una charla informal el miércoles 21 de mayo a las 10:00 a.m. ET en Nueva York. Los inversores y partes interesadas podrán acceder a una transmisión en vivo de la presentación a través del sitio web de relaciones con inversores de la empresa, con una repetición disponible después del evento.
Karyopharm Therapeutics (나스�: KPTI), 혁신적인 � 치료제에 중점� � 상업 단계 제약 회사가 2025 RBC 캐피� 마켓 글로벌 헬스케� 컨퍼런스� 참여한다� 발표했습니다. 회사� 고위 경영진은 5� 21� 수요� 오전 10�(동부시간) 뉴욕에서 열린 파이어사이드 채팅� 참석� 예정입니�. 투자자와 관� 있는 분들은 회사� 투자� 관� 웹사이트� 통해 발표� 실시� 웹캐스트� 시청� � 있으�, 행사 � 다시보기 서비스도 제공됩니�.
Karyopharm Therapeutics (Nasdaq : KPTI), une entreprise pharmaceutique en phase commerciale spécialisée dans les thérapies innovantes contre le cancer, a annoncé sa participation à la 2025 RBC Capital Markets Global Healthcare Conference. L'équipe de direction senior de la société participera à une discussion informelle le mercredi 21 mai à 10h00 ET à New York. Les investisseurs et les parties intéressées pourront suivre la présentation en direct via le site web des relations investisseurs de la société, avec une rediffusion disponible après l'événement.
Karyopharm Therapeutics (Nasdaq: KPTI), ein pharmazeutisches Unternehmen in der kommerziellen Phase mit Fokus auf neuartige Krebstherapien, hat seine Teilnahme an der 2025 RBC Capital Markets Global Healthcare Conference angekündigt. Das leitende Management des Unternehmens wird am Mittwoch, den 21. Mai um 10:00 Uhr ET in New York an einem Fireside-Chat teilnehmen. Investoren und Interessierte können die Präsentation live über die Investor-Relations-Website des Unternehmens verfolgen, eine Wiederholung wird nach der Veranstaltung verfügbar sein.
- None.
- None.
A live webcast of the fireside chat can be accessed under "Events & Presentations" in the Investor section of the Company's website, , and will be available for replay following the event.
About Karyopharm Therapeutics
Karyopharm Therapeutics Inc. (Nasdaq: KPTI) is a commercial-stage pharmaceutical company whose dedication to pioneering novel cancer therapies is fueled by a belief in the extraordinary strength and courage of patients with cancer. Since its founding, Karyopharm has been an industry leader in oral compounds that address nuclear export dysregulation, a fundamental mechanism of oncogenesis. Karyopharm's lead compound and firstinclass, oral exportin 1 (XPO1) inhibitor, XPOVIO® (selinexor), is approved in the
XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. Any other trademarks referred to in this release are the property of their respective owners.
View original content to download multimedia:
SOURCE Karyopharm Therapeutics Inc.